In Alzheimer’s disease, which is characterized by accumulation of amyloid-β (Aβ) and tau aggregates, EGCG was shown to be an effective inhibitor of tau aggregation and toxicity, which could be beneficial to hinder Alzheimer’s progression [90]. This evidence concerns the gene MAPT and early-onset autosomal dominant Alzheimer disease.